MINUTES OF MEETING - March 6-7 
20 
that the institution determine the necessity for health surveillance 
but do not mandate any required health surveillance program, and 
that health surveillance varies from university to university. 
Dr. Brill moved acceptance of Dr. Yoder's request at the P2 level of 
physical containment. Dr. Zaitlin absented himself during the vote. 
The RAC recommended approval of the request at the P2 level of contain- 
ment by a vote of eight in favor, none opposed, and nine abstentions, 
including Dr. Zaitlin. 
B. Request to evaluate containment appropriate to returning 
Schizophyllum corrmune ENA cloned in yeast to the host of origin 
Dr. Broadbent said that tab 831 (843/11) concerns a request from 
Dr. Marvin Schwalb of the New Jersey Medical School to consider con- 
tainment levels appropriate for the return of Schizophyllum commune 
DNA cloned in Saccharomyces cerevisiae to Schizophyllum commune . 
Dr. Broadbent said Dr. Schwalb also requests permission to clone the 
Saccharomyces cerevisiae derived vector YR414/ura 3 or the Saccharo- 
myces cerevisiae 2 my plasmid containing Saccharomyces cerevisiae or 
Schizophyllum commune sequences in Schizophyllum commune . He said 
Dr. Schwalb is proposing to use P2 physical containment levels. 
Dr. Broadbent said that Schizophyllum commune is a non-pa thogenic 
basidiomycete which is widespread in nature. He said Schizophyllum 
corrmune does not form asexual spores, and forms spores only under 
easily controllable genetic and environmental conditions. He recom- 
mended approval at the P2 level of containment. Dr. Williams and 
Young concurred, noting that the organism is well controlled under 
laboratory conditions and that asexual sporulation does not occur. 
Dr. Walters pointed out that in a letter of December 13, 1979, 
Dr. Schwalb suggests that Schizophyllum commune be considered as an 
HVl system. Drs. Young and Gottesman said that approval for the 
specific experiment is being considered, and HVl certification of 
Schizophyllum commune is not under consideration. 
Dr. Broadbent moved approval of the preposed experiments at P2 physical 
containment. The motion passed by a vote of eighteen in favor, none 
opposed, and one abstention. 
C. Consideration of appropriate containment for cloning Wangiella 
dermatitidis ENA 
Dr. Broadbent presented the proposal of Dr. Charles Jacobs of the 
University of Texas at Austin (tab 832, 860, 843/17). He said 
Dr. Jacobs requests permission to clone Wangiella dermatitidis ENA 
in Wangiella dermatitidis using a Saccharomyces cerevisiae/Escherichia 
coli hybrid plasmid as vector. 
[ 55 ] 
